A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 38/21 (2006.01) A61K 31/4545 (2006.01) A61K 31/496 (2006.01) A61P 31/18 (2006.01)
Patent
CA 2365900
The use of a pegylated interferon-alfa and a CCR5 antagonist, further in association with at least one of ribavirin, IL-2, IL-12, pentafuside alone or in combination with an anti-HIV-1 drug therapy, e.g., HAART, for preparation of a medicament for the treatment of HIV-1 infections as well as HIV-1 infections as well as HIV-1 and HCV co-infections in treatment-naive as well as treatment-experienced adult and pediatric patients are disclosed.
L'invention concerne l'utilisation d'un PEG-interféron-alpha et d'un antagoniste CCR5, associés à l'un des constituants suivants: la ribavirine, IL-2, IL-12, et la pentafuside employée seule ou en combinaison avec une pharmacothérapie anti-VIH-1, par exemple HAART, ce qui permet de préparer un médicament destiné à traiter les infections à VIH-1 ainsi que les co-infections à VIH-1 et HCV, chez des patients adultes et pédiatriques soumis pour la première fois à un traitement ou ayant déjà subi un traitement.
Norton Rose Or S.e.n.c.r.l. S.r.l./llp
Schering Corporation
LandOfFree
Pegylated interferon alfa-ccr5 antagonist combination hiv... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pegylated interferon alfa-ccr5 antagonist combination hiv..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pegylated interferon alfa-ccr5 antagonist combination hiv... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1721865